
...BIBLIOGRAPHY...

- Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. *Arterioscler Thromb Vasc Biol* 1997;17:217-221.
- Allen R, Scheidt S. Stress, anger, and psychosocial factors for coronary heart disease. In: Manson JE, Ridker PM, Gaziano JM, Hennekens CH, eds. *Prevention and Myocardial Infarction*. New York, NY: Oxford University Press; 1996:274-307.
- American Cancer Society. *Cancer Facts & Figures—1997*. Atlanta, GA: American Cancer Society; 1997.
- American College of Obstetricians and Gynecologists. ACOG committee opinion: Tamoxifen and endometrial cancer. *Int J Gynecol Obstet* 1996;53:197-199.
- Anderson HV. Estrogen therapy, atherosclerosis, and clinical cardiovascular events. *Circulation* 1996;94:1809-1811.
- Anderson RN, Kochanek KD, Murphy SL. Report of final mortality statistics, 1995. *Monthly Vital Statistics Report* 1997;45(suppl 2):26.
- Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. *Am J Cardiol* 1998;81(4A):7B-12B.
- Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. *JAMA* 1991;265:1861-1867.
- Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. *Ann Rev Public Health* 1998;19:55-72.
- Barrett-Connor E, Wenger NK, Grady D, et al. Coronary heart disease in women: Randomized clinical trials, HERS and RUTH. *Maturitas* 1998;31:1-7.
- Barrett-Connor E, Wenger NK, Grady D, et al. Hormone and nonhormone therapy for the maintenance of postmenopausal health: The need for randomized controlled trials of estrogen and raloxifene. *J Womens Health* 1998;7:839-847.
- Barrett-Connor E. Postmenopausal estrogen and prevention bias. *Ann Intern Med* 1991;115:455-456.
- Bilimoria MM, Jordan VC. Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer? *Semin Surg Oncol* 1996;12:339-345.
- Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. *Circulation* 1997;96:1964-1969.
- Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. *Lancet* 1996;348:1535-1541.
- Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. *J Clin Invest* 1994;93:63-69.
- Blackman MR, Kern DE. Clinical implications of abnormal lipoprotein metabolism. In: Barker LR, Burton JR, Zieve PD, eds. *Principles of Ambulatory Medicine*, 3rd ed. Baltimore, MD: Williams and Wilkins; 1991:1004-1028.
- Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. *Am J Obstet Gynecol* 1997;177:1458-1464.
- Brannon R, Orrick S. Women and managed care: The employer's perspective. *Womens Health Issues* 1998;8:15-24.
- Brown KH, Hammond CB. Urogenital atrophy. *Obstet Gynecol Clin North Am* 1987;15:13-32.
- Bryant HU, Dere WH. Selective estrogen receptor modulators: An alternative to hormone replacement therapy. *Proc Soc Exp Biol Med* 1998;217:45-52.
- Bryant HU, Wilson PK, Adrian MD. Selective estrogen receptor modulators: Pharmacologic profile in the rat uterus. *J Soc Gynecol Invest* 1996;3(suppl):152A.
- Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. *Circulation* 1987;75:1102-1109.
- Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. *Ann NY Acad Sci* 1990;592:263-271.
- Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy. *J Clin Oncol* 1998;16:348-353.

... BIBLIOGRAPHY ...

- Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. *N Engl J Med* 1986;314:1615-1620.
- Chu J, Schweid AI, Weiss NS. Survival among women with endometrial cancer: A comparison of estrogen users and nonusers. *Am J Obstet Gynecol* 1982;143:569-573.
- Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. *J Clin Endocrinol Metab* 1998;83:721-726.
- Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. *N Engl J Med* 1987;316:1105-1110.
- Collins J, Allen LH, Donner A, Adams O. Oestrogen use and survival in endometrial cancer. *Lancet* 1980;2:961-964.
- Cook LS, Weiss NS, Schwartz SM, et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. *J Natl Cancer Inst* 1995;87:1359-1364.
- Cope E. Physical changes associated with the postmenopausal years. In: Campbell S, ed. *The Management of the Menopause & Post-Menopausal Years*. Baltimore, MD: University Park Press; 1976:29-42.
- Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. *J Natl Cancer Inst* 1997;89:776-782.
- Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ. Epidemiology of osteoporosis and osteoporotic fractures. *Epidemiol Rev* 1985;7:178-208.
- Cummings SR, Norton L, Eckert S, et al. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. *Proc Am Soc Clin Oncol* 1998;17:2a. Abstract 3.
- Cummings SR, Rubin SM, Black D. The future of hip fractures in the United States: Numbers, costs, and potential effects of postmenopausal estrogen. *Clin Orthop* 1990;March:163-166.
- Davis BJ, Maronpot RR. Chemically associated toxicity and carcinogenicity of the ovary. In: Huff J, Boyd J, Barrett JC, eds. *Cellular and Molecular Mechanisms of Hormonal Carcinogenesis: Environmental Influences*. New York, NY: Wiley-Liss, Inc; 1996:285-308.
- Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. *N Engl J Med* 1997;337:1641-1647.
- Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. *Control Clin Trials* 1998;19:61-109.
- Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. *JAMA* 1998;279:1615-1622.
- Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. *J Bone Miner Res* 1996;11:835-842.
- Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. *Lancet* 1998;351:1451-1467.
- England MJ, Muchnick-Baku S. Women and managed care. *JAMWA* 1997;52:81-82.
- Ensrud K, Black D, Recker R, et al. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. *Bone* 1998;23(No. 5, suppl):S174. Abstract 1105.
- Ettinger B, Black D, Cummings S, et al. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses. *Osteoporosis Int* 1998;8(suppl 3):11. Abstract.
- Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. *N Engl J Med* 1993;329:1141-1146.
- Ferguson KJ, Hoegh C, Johnson S. Estrogen replacement therapy: A survey of women's knowledge and attitudes. *Arch Intern Med* 1989;149:133-136.
- Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. *J Natl Cancer Inst* 1994;86:527-537.
- Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst* 1998;90:1371-1388.

... BIBLIOGRAPHY ...

- Fuleihan GE-H. Tissue-specific estrogens—The promise for the future. *N Engl J Med* 1997;337:1686-1687.
- Gal D, Kopel S, Bashevkin M, Lebowicz J, Lev R, Tancer ML. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer—Preliminary report. *Gynecol Oncol* 1991;42:120-123.
- Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. *JAMA* 1993;270:742-744.
- *Gallup Survey Findings: Overview of Perceived and Real Health Threats*. New York, NY: Gallup survey; 1995.
- Gambrell RD Jr. Use of progestogen therapy. *Am J Obstet Gynecol* 1987;156:1304-1313.
- Geola FL, Frumar AM, Tataryn IV, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. *J Clin Endocrinol Metab* 1980;51:620-625.
- Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. *Circulation* 1995;92:5-8.
- Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. *Circulation* 1998;98:1158-1163.
- Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. *Ann Intern Med* 1992;117:1016-1037.
- Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. *J Clin Endocrinol Metab* 1995;80:3191-3195.
- Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. *Am J Med* 1995;99:636-641.
- Guetta V, Cannon RO III. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. *Circulation* 1996;93:1928-1937.
- Hahn RG. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors. *Am J Obstet Gynecol* 1989;161:1854-1858.
- Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy: II. Neoplasia. *Am J Obstet Gynecol* 1979;33:525-536.
- Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. *J Clin Oncol* 1995;13:2556-2566.
- Heaney RP, Draper MW. Raloxifene and estrogen: Comparative bone-remodeling kinetics. *J Clin Endocrinol Metab* 1997;82:3425-3429.
- Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials. *BMJ* 1997;315:149-153.
- Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. *Lancet* 1990;336:542-545.
- Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA* 1998;280:605-613.
- Ilanchezhian S, Thangaraju M, Sachdanandam P. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status. *Cancer Biochem Biophys* 1995;15:83-90.
- Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, eds. *Harrison's Principles of Internal Medicine*, 13th ed. New York, NY: McGraw-Hill, Inc.; 1994:2021.
- Johannes CB, Crawford SL, Posner JG, McKinlay SM. Longitudinal patterns and correlates of hormone replacement therapy use in middle-aged women. *Am J Epidemiol* 1994;140:439-452.
- Jordan VC. Designer estrogens. *Sci Am* 1998;October: 60-67.
- Jordan VC. The clinical development of tamoxifen. In: Jordan VC, ed. *Tamoxifen: A Guide for Clinicians and Patients*. Huntington, NY: PRR; 1996:25-36.

... BIBLIOGRAPHY ...

- Jordan VC. Why tamoxifen? In: Jordan VC, ed. *Tamoxifen: A Guide for Clinicians and Patients*. Huntington, NY: PRR; 1996:15-23.
- Kannel WB. High-density lipoproteins: Epidemiologic profile and risks of coronary artery disease. *Am J Cardiol* 1983;52:9B-12B.
- Kannel WB. Influence of fibrinogen on cardiovascular disease. *Drugs* 1997;54(suppl 3):32-40.
- Kauffman RF, Bensch WR, Roudebush RE, et al. Hypocholesterolemic activity of raloxifene (LY139481): Pharmacological characterization as a selective estrogen receptor modulator. *J Pharmacol Exp Ther* 1997;280:146-153.
- Kenny AM, Prestwood KM, Pilbeam CC, Raisz LG. The short term effects of tamoxifen on bone turnover in older women. *J Clin Endocrinol Metab* 1995;80:3287-3291.
- Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowicz MA. Hip fracture and the use of estrogens in postmenopausal women: The Framingham Study. *N Engl J Med* 1987;317:1169-1174.
- Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. *N Engl J Med* 1995;333:1437-1443.
- Lindsay R, Cosman F, Nieves J. Estrogen: Effects and actions in osteoporosis. *Osteoporosis Int* 1993;(suppl 1):S150-S152.
- Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. *Lancet* 1980;2:1151-1153.
- Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. *Obstet Gynecol* 1990;76:290-295.
- Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *JAMA* 1984;251:365-374.
- Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. *Arch Intern Med* 1994;154:2585-2588.
- Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. *N Engl J Med* 1992;326:852-856.
- Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. *Arch Intern Med* 1992;152:317-320.
- Love RR. Issues in the design of a tamoxifen health trial. In: Williams CJ, ed. *Introducing New Treatments for Cancer: Practical, Ethical and Legal Problems*. Chichester, UK: John Wiley and Sons; 1992:341-356.
- Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. *Ann Intern Med* 1992;117:1-9.
- Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. *J Bone Miner Res* 1998;13:1747-1754.
- Mack TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. *N Engl J Med* 1976;294:1262-1267.
- Managed Medicare's rapid expansion. *Managed Care* 1997;6:61-64.
- Mandel FP, Geola FL, Meldrum DR, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. *J Clin Endocrinol Metab* 1983;57:133-139.
- Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women: Review of an NHLBI workshop. *Ann Epidemiol* 1992;2:161-176.
- Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? *Am J Epidemiol* 1996;10:971-978.
- McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. *BMJ* 1995;311:977-980.
- McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Scottish Breast Cancer Committee. *BMJ* 1991;303:435-437.

... BIBLIOGRAPHY ...

- McDonald TW, Annegers JF, O'Fallon WM, Dockerty MB, Malkasian GD Jr, Kurland LT. Exogenous estrogen and endometrial carcinoma: Case-control and incidence study. *Am J Obstet Gynecol* 1977;127:572-580.
- Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis? *J Bone Miner Res* 1992;7:1005-1010.
- Melton LJ III. Epidemiology of age-related fractures. In: Avioli LV, ed. *The Osteoporotic Syndrome: Detection, Prevention, and Treatment*, 3rd ed. New York, NY: Wiley-Liss; 1993:17-38.
- Melton LJ III. How many women have osteoporosis now? *J Bone Miner Res* 1995;10:175-177.
- Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. *Am Heart J* 1987;113:589-597.
- Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators. *Horm Res* 1997;48:155-163.
- Miyagawa K, Rösch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. *Nat Med* 1997;3:324-327.
- Mosca L, Grundy S, Judelson D, et al. AHA/ACC Medical/Scientific Consensus Panel statement: A guide to preventive cardiology for women. *Circulation* In press.
- Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: A statement for healthcare professionals from the American Heart Association. *Circulation* 1997;96:2468-2482.
- Mosca L. Estrogen and atherosclerosis. *J Invest Med* 1998;46:381-386.
- Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. *Obstet Gynecol* 1979;54:74-79.
- National Center for Health Statistics. *Health, United States, 1998: With Socioeconomic Status and Health Chartbook*. Hyattsville, MD: US Department of Health and Human Services; 1998:365.
- Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder E. Hysteroscopic follow-up during tamoxifen treatment. *Eur J Obstet Gynecol Reprod Biol* 1990;35:235-238.
- 1995 AAHP HMO PPO Trends Report. Washington, DC: American Association of Health Plans; 1997.
- 1997 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 1996:3, 6, 11, 28.
- Notelovitz M. Gynecologic problems of menopausal women: Part 1. Changes in genital tissue. *Geriatrics* 1978;August:24-30.
- Paganini-Hill A, Chao A, Ross RK, Henderson BE. Exercise and other factors in the prevention of hip fracture: The Leisure World study. *Epidemiology* 1991;2:16-25.
- Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. *CA Cancer J Clin* 1997;47:5-27.
- Persson I, Adami H-O, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. *Br Med J* 1989;298:147-151.
- *Physicians' Desk Reference*, 53rd ed. Montvale, NJ: Medical Economics Company; 1999:1321-1323, 1576-1579, 2842-2843.
- *Physicians' Desk Reference*, 52nd ed. Montvale, NJ: Medical Economics Company, Inc; 1998:3111.
- Pickar JH, Thorneycroft I, Whitehead M. Effects of hormone replacement therapy on the endometrium and lipid parameters: A review of randomized clinical trials, 1985 to 1995. *Am J Obstet Gynecol* 1998;178:1087-1099.
- Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. *J Clin Oncol* 1996;14:78-84.
- Prestwood KM, Pilbeam CC, Burtleson JA, et al. The short term effects of conjugated estrogen on bone turnover in older women. *J Clin Endocrinol Metab* 1994;79:366-371.
- Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. *J Bone Miner Res* 1997;12:24-35.

... BIBLIOGRAPHY ...

- Register TC, Adams MR, Golden DL, Clarkson TB. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. *Arterioscler Thromb Vasc Biol* 1998;18:1164-1171.
- Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. *N Engl J Med* 1992;327:620-627.
- Ross PD. Osteoporosis: Frequency, consequences, and risk factors. *Arch Intern Med* 1996;156:1399-1411.
- Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. Stockholm Breast Cancer Study Group. *J Natl Cancer Inst* 1993;85:1398-1406.
- Saarto T, Blomqvist C, Ehnholm C, Taskinen M-R, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. *J Clin Oncol* 1996;14:429-433.
- Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med* 1996;355:1001-1009.
- Salamone LM, Pressman AR, Seeley DG, Cauley JA. Estrogen replacement therapy: A survey of older women's attitudes. *Arch Intern Med* 1996;156:1293-1297.
- Sato M, Bryant HU, Iversen P, et al. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. *J Pharmacol Exp Ther* 1996;279:298-305.
- Sato M, Glasebrook AL, Bryant HU. Raloxifene: A selective estrogen receptor modulator. *J Bone Miner Metab* 1994;12(suppl 2):S9-S20.
- Scheele WH, Symanowski SM, Neale S, et al. Raloxifene does not cause stimulatory effects on the uterus in healthy postmenopausal women. Program and Abstracts of the 79th Annual Meeting of the Endocrine Society; June 11-14, 1997; Abstract P3-246.
- Schwartz LB, Snyder J, Horan C, Porges RF, Nachtigall LE, Goldstein SR. The use of transvaginal ultrasound and saline infusion sonohysterography for the evaluation of asymptomatic postmenopausal breast cancer patients on tamoxifen. *Ultrasound Obstet Gynecol* 1998;11:48-53.
- Selzman CH, Whitehill TA, Shames DB, Pulido EJ, Cain BC, Harken AH. The biology of estrogen-mediated repair of cardiovascular injury. *Ann Thorac Surg* 1998;65:868-874.
- Semmens JP, Tsai CC, Semmens EC, Loadholt CB. Effects of estrogen therapy on vaginal physiology during menopause. *Obstet Gynecol* 1985;66:15-18.
- Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. *Arterioscler Thromb* 1994;14:1586-1593.
- Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone mineral density information on decisions about hormone replacement therapy: A randomized trial. *Obstet Gynecol* 1997;89:321-325.
- Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. *N Engl J Med* 1975;293:1164-1167.
- Stafford RS, Saglam D, Causino N, Blumenthal D. Low rates of hormone replacement in visits to United States primary care physicians. *Am J Obstet Gynecol* 1997;177:381-387.
- Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. *Prev Med* 1991;20:47-63.
- Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F. A randomized study on the effects of oestrogen-gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. *Bone* 1989;10:313-320.
- Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. *JAMA* 1993;269:3015-3023.
- Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. *Cancer* 1994;73:659-663.
- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *JAMA* 1995;273:199-208.

... BIBLIOGRAPHY ...

- The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *JAMA* 1996;276:1389-1396.
- Tomás E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. *Gynecol Oncol* 1995;59:261-266.
- Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. *Lancet* 1998;351:1425-1427.
- US Bureau of the Census. *Current Population Reports: Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050*. Washington, DC: US Government Printing Office; 1996:48, 72, 78, 80, 88. Publication number P25-1130.
- US Preventive Services Task Force. *Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force*, 2nd ed. Baltimore, MD: Williams & Wilkins; 1996:xxv, xxvi, 76, 108.
- Utian WH, Schiff I. NAMS—Gallup Survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. *Menopause J North Am Menopause Soc* 1994;1:39-48.
- Vedi S, Compston JE. The effects of long-term hormone replacement therapy on bone remodeling in postmenopausal women. *Bone* 1996;19:535-539.
- Vickers MR, Meade TW, Wilkes HC. Hormone replacement therapy and cardiovascular disease: The case for a randomized controlled trial. *CIBA Found Symp* 1995;191:150-164.
- Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. *JAMA* 1998;279:1445-1451.
- Wiernicki T, Glasebrook A, Phillips DL, Singh J. Estrogen and a novel tissue selective estrogen receptor modulator raloxifene directly modulate vascular smooth muscle cell functions: Implications in the cardioprotective mechanism of estrogen. *Circulation* 1998;94(suppl 1):I-278.
- Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity on atherosclerotic coronary arteries in cynomolgus monkeys. *J Am Coll Cardiol* 1994;24:1757-1761.
- Wiseman H. Tamoxifen as an antioxidant and cardioprotectant. *Biochem Soc Symp* 1995;61:209-219.
- Woodruff JD, Pickar JH, for the Menopause Study Group: Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. *Am J Obstet Gynecol* 1994;170:1213-1223.
- Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women: The Scottish Heart Health Study. *Eur Heart J* 1998;19:55-62.
- World Health Organization. *Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis: Report of a WHO Study Group*. Geneva, Switzerland: World Health Organization; 1994:2-6, 18, 19. Technical Report Series 843.
- Wright CDP, Garrahan NJ, Stanton M, Gazet J-C, Mansell RE, Compston JE. Effect of long-term tamoxifen therapy on cancellous bone remodeling and structure in women with breast cancer. *J Bone Miner Res* 1994;9:153-159.
- Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17 β -estradiol and raloxifene. *Science* 1996;273:1222-1225.
- Ziel HK, Finkle WD. Association of estrone with the development of endometrial carcinoma. *Am J Obstet Gynecol* 1976;124:735-740.
- Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). *Atherosclerosis* 1996;126:65-75.